← Back to Search

Black patients with advanced cancer for Cancer (EDPO Trial)

N/A
Recruiting
Led By Bryan P Schneider, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion (i.e. death, lost to follow up, or withdraw)-up to 5 years
Awards & highlights

EDPO Trial Summary

This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.

Eligible Conditions
  • Cancer

EDPO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion (i.e. death, lost to follow up, or withdraw)-up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion (i.e. death, lost to follow up, or withdraw)-up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Compare Overall Survival between Black patients and White patients (self-reported race) with advanced cancer
Compare rate of new onset or worsening therapy- induced peripheral neuropathy (TIPN) between Black patients and White patients with advanced cancer prospectively exposed to a taxane
Secondary outcome measures
Assess the impact of toxicity as measured by dose reductions or dose cessations attributed to TIPN from chart review measured as RDI, a function of the ratio of received to intended doses, and thus accounts for differences in drugs or time of therapy
Assess the significance of key attributes (clinical demographics, SDoH, host genomics and prior therapy exposures) on therapy-induced neuropathy
Assess the significance of key attributes (tumor genomics, clinical demographics, SDoH, access, and the intersection of tumor biology and drug impact) on efficacy, and survival outcomes
+7 more

EDPO Trial Design

2Treatment groups
Experimental Treatment
Group I: Non Black patients with advanced cancerExperimental Treatment1 Intervention
Group II: Black patients with advanced cancerExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
980 Previous Clinical Trials
972,676 Total Patients Enrolled
Bryan P Schneider, MDPrincipal InvestigatorIndiana University
2 Previous Clinical Trials
677 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluating Disparities in Precision Oncology
Bryan Schneider 2024. "Evaluating Disparities in Precision Oncology". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06081517.
All > Indianapolis
~7067 spots leftby Jul 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top